FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2274289318> ?p ?o ?g. }

• W2274289318 endingPage "18218" @default.
• W2274289318 startingPage "18204" @default.
• W2274289318 abstract "Chronic myeloid leukaemia (CML) is a myeloproliferative disorder promoted by the constitutive tyrosine kinase activity of Bcr-Abl oncoprotein. Although treatment with the Bcr-Abl-inhibitor imatinib represents the first-line therapy against CML, almost 20-30% of patients develop chemotherapeutic resistance and require alternative therapy. Here we show that a strong hyper-phosphorylation/activation of ERK1/2, Akt Ser473, and 40S ribosomal protein S6 (rpS6) is detectable in imatinib-resistant KCL22 and K562 CML cells as compared to the -sensitive cell variants. In imatinib-resistant CML cells, high concentration of imatinib is required to strongly inhibit Bcr-Abl, ERK1/2 and Akt Ser473 phosphorylation, but under these conditions the phosphorylation of rpS6, a common downstream effector of MEK/ERK1/2 and PI3K/Akt/mTOR pathways is only slightly reduced. By contrast, down-regulation of the protein kinase CK2 by the inhibitor CX-5011 or by silencing the CK2 subunits does not affect the activation state of MEK/ERK1/2 or PI3K/Akt/mTOR signalling, but causes a drop in rpS6 phosphorylation in parallel with reduced protein synthesis. CK2-inhibition by CX-5011 induces cell death by apoptosis and acts synergistically with imatinib or the MEK-inhibitor U0126 in reducing the viability of imatinib-resistant CML cells. The ternary mixture containing CX-5011, imatinib and U0126 represents the most effective synergistic combination to counteract CML cell viability. These results disclose a novel CK2-mediated mechanism of acquired imatinib-resistance resulting in hyper-phosphorylation of rpS6. We suggest that co-targeting CK2 and MEK protein kinases is a promising strategy to restore responsiveness of resistant CML cells to imatinib." @default.
• W2274289318 created "2016-06-24" @default.
• W2274289318 creator A5029122382 @default.
• W2274289318 creator A5034957734 @default.
• W2274289318 creator A5042203481 @default.
• W2274289318 creator A5052547325 @default.
• W2274289318 creator A5058504277 @default.
• W2274289318 date "2016-02-22" @default.
• W2274289318 modified "2023-10-18" @default.
• W2274289318 title "Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies" @default.
• W2274289318 cites W1479869774 @default.
• W2274289318 cites W1483741433 @default.
• W2274289318 cites W1557329138 @default.
• W2274289318 cites W1908445283 @default.
• W2274289318 cites W1969375092 @default.
• W2274289318 cites W1974120504 @default.
• W2274289318 cites W1981387221 @default.
• W2274289318 cites W1984132097 @default.
• W2274289318 cites W1988769784 @default.
• W2274289318 cites W1990406235 @default.
• W2274289318 cites W1995306431 @default.
• W2274289318 cites W1996165605 @default.
• W2274289318 cites W1996547558 @default.
• W2274289318 cites W2002631048 @default.
• W2274289318 cites W2005443228 @default.
• W2274289318 cites W2009164057 @default.
• W2274289318 cites W2024750925 @default.
• W2274289318 cites W2025273907 @default.
• W2274289318 cites W2025950197 @default.
• W2274289318 cites W2032511861 @default.
• W2274289318 cites W2041308494 @default.
• W2274289318 cites W2042638141 @default.
• W2274289318 cites W2045795713 @default.
• W2274289318 cites W2055729918 @default.
• W2274289318 cites W2056638998 @default.
• W2274289318 cites W2064854415 @default.
• W2274289318 cites W2066967369 @default.
• W2274289318 cites W2075155467 @default.
• W2274289318 cites W2076807264 @default.
• W2274289318 cites W2077385921 @default.
• W2274289318 cites W2081681244 @default.
• W2274289318 cites W2082935152 @default.
• W2274289318 cites W2085007060 @default.
• W2274289318 cites W2086262311 @default.
• W2274289318 cites W2087379913 @default.
• W2274289318 cites W2088938650 @default.
• W2274289318 cites W2095510836 @default.
• W2274289318 cites W2103562758 @default.
• W2274289318 cites W2109990271 @default.
• W2274289318 cites W2119924449 @default.
• W2274289318 cites W2129881449 @default.
• W2274289318 cites W2134138119 @default.
• W2274289318 cites W2142419137 @default.
• W2274289318 cites W2144770959 @default.
• W2274289318 cites W2145678539 @default.
• W2274289318 cites W2152648806 @default.
• W2274289318 cites W2159963744 @default.
• W2274289318 cites W2160226692 @default.
• W2274289318 cites W2166342674 @default.
• W2274289318 cites W2312282875 @default.
• W2274289318 doi "https://doi.org/10.18632/oncotarget.7569" @default.
• W2274289318 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4951282" @default.
• W2274289318 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26919095" @default.
• W2274289318 hasPublicationYear "2016" @default.
• W2274289318 type Work @default.
• W2274289318 sameAs 2274289318 @default.
• W2274289318 citedByCount "18" @default.
• W2274289318 countsByYear W22742893182016 @default.
• W2274289318 countsByYear W22742893182017 @default.
• W2274289318 countsByYear W22742893182018 @default.
• W2274289318 countsByYear W22742893182019 @default.
• W2274289318 countsByYear W22742893182020 @default.
• W2274289318 countsByYear W22742893182021 @default.
• W2274289318 countsByYear W22742893182022 @default.
• W2274289318 crossrefType "journal-article" @default.
• W2274289318 hasAuthorship W2274289318A5029122382 @default.
• W2274289318 hasAuthorship W2274289318A5034957734 @default.
• W2274289318 hasAuthorship W2274289318A5042203481 @default.
• W2274289318 hasAuthorship W2274289318A5052547325 @default.
• W2274289318 hasAuthorship W2274289318A5058504277 @default.
• W2274289318 hasBestOaLocation W22742893181 @default.
• W2274289318 hasConcept C104202773 @default.
• W2274289318 hasConcept C11960822 @default.
• W2274289318 hasConcept C185592680 @default.
• W2274289318 hasConcept C2777583451 @default.
• W2274289318 hasConcept C2778729363 @default.
• W2274289318 hasConcept C2780926556 @default.
• W2274289318 hasConcept C3019892230 @default.
• W2274289318 hasConcept C502942594 @default.
• W2274289318 hasConcept C62478195 @default.
• W2274289318 hasConcept C71924100 @default.
• W2274289318 hasConcept C75217442 @default.
• W2274289318 hasConcept C86554907 @default.
• W2274289318 hasConcept C86803240 @default.
• W2274289318 hasConcept C95444343 @default.
• W2274289318 hasConceptScore W2274289318C104202773 @default.
• W2274289318 hasConceptScore W2274289318C11960822 @default.
• W2274289318 hasConceptScore W2274289318C185592680 @default.

• next